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The aim of nebuliser therapy is to deliver a therapeutic dose of the desired drug in the form
Fill volume: the volume of drug solution initially put into the nebuliser chamber. It must exceed of an aerosol of respirable particles within a fairly short period of time, usually the residual volume by a sufficient amount to provide therapeutic benefit to the patient. 9 It is 5-15 minutes. To achieve this, nebuliser systems should be expected to provide a drug suggested that it should be at least twice the residual volume. It is important to be aware output with about 50% of the particles below 5.0 m mass median diameter. It is important of the desirable fill volume when prescribing nebuliser drugs in prepackaged ampoules. to obtain an acceptable range of aerosol particle sizes because of the way in which these are
The definitions of aerosol output, respirable particles, mass median diameter (MMD), mass deposited in the tracheobronchial tree. [1] [2] [3] [4] [5] median aerodynamic diameter (MMAD), respirable output, and respirable fraction are given in the paper by O'Callaghan and Barry Practical definitions on page S35. Jet nebuliser: a nebulising chamber where an aerosol is generated from a flow of gas from an electrical compressor or from a compressed gas supply (air or oxygen). The gas passes through Factors affecting nebuliser performance
The general term "nebuliser" usually implies a very small hole (the jet or Venturi) resulting in liquid being sucked up through the small the combination of the nebuliser chamber and the compressor. Jet nebulisers usually have a hole from the chamber base and atomised. The resultant large particles then impact upon constant output, but to prevent wastage new breath-enhanced nebulisers are available where baffles to generate small respirable particles. 6 Ultrasonic nebuliser: an electrically driven sys-the output is enhanced in the inhalation phase.
Ultrasonic nebulisers are effective but are less tem whereby a rapidly vibrating piezoelectric crystal vibrates the drug solution and produces robust and more expensive than jet nebuliser systems and are generally not used for regular aerosol particles of a respirable size. 6 Flow rate through the nebuliser: the flow rate domiciliary therapy.
The major use of nebuliser systems is to of gas, whether from a compressed source or from a compressor, that actually drives the deliver bronchodilator therapy. The specification of the nebuliser chamber for adnebuliser chamber. It is not the same as the flow rate from the compressor which will often ministering bronchodilators is different from that required to deliver other drugs such as be considerably higher. 7 It is obtained by producing a pressure-flow rate curve for the nebu-antibiotics or pentamidine.
The output of a nebuliser is determined by liser. Recordings of circuit pressure are made from zero flow (maximum pressure) to max-a combination of factors which must be taken into account, and will depend on (1) the design imum flow (minimum pressure) using a rotameter, a compressor unit (or flow generator), of the nebuliser chamber, 6 (2) the flow of the driving gas and the performance characteristics and pressure measuring device. By substituting the nebuliser chamber for the rotameter the of the compressor, 7 10 11 (3) the volume of solution (fill volume) of the drug at the start of nebupressure in the circuit can be obtained with a ticular types of nebuliser or combinations of nebuliser and compressor will be required. The final choice of equipment should be made by the staff of the local unit and not by supplies departments acting in isolation.
Specific information will be required to assist the choice. For the nebuliser this should include data on the flow rate at the nebuliser, residual volume, maximum fill volume, the volume (or drug) output at five and 10 minutes, the MMD (or MMAD), and the percentage of particles under 5 m. For the compressor the size, also be obtained.
Selecting nebulisers and compressors
The choice of nebuliser and compressor depends on various factors including cost, ease Nebuliser/compressor combinations The performance of a given nebuliser chamber of use and of maintenance, and overall performance. There are many nebuliser chambers is closely linked to the flow of the driving gas and, hence, the performance of the compressor and compressors available. Choice should be based on assessment of the systems and com-chosen to drive the nebuliser chamber. 7 It is therefore important to use a combination ments from other users. It is not advisable simply to pick a nebuliser chamber and a com-of nebuliser chamber and compressor that delivers an acceptable volume output of drug, pressor at random. As will be discussed below, the matching of a nebuliser and compressor with an acceptable range of respirable particles, over an acceptable period of time to the is important to achieve optimal performance. Furthermore, under certain circumstances par-patient. 7 12 16-23 The data in this table have been compiled from various sources and provide a guide only. Whilst the residual and maximum fill volumes are accurate, the percentage of solution nebulised at 5 and 10 minutes is the best figure obtainable. This has been obtained for a fill volume of 2-2.5 ml and is generally taken from data obtained with its retail compressor. The % of particles under 5 m is taken from various sources. Where a ? appears there are no data currently available from any known source. * Depends on configuration of nebuliser chamber (Type 2) and on type of compressor unit. Data are for diaphragm/rotary piston compressors. † Data with pentamidine.
  poor performance system has resulted in either a reduction in the quality of life or increase in We have divided some currently available nebuliser/compressor combinations into three bands hospital admissions. Part of the reason for this is probably that the doses of bronchodilator based on the flow rate at the nebuliser (table  1) . High flow rate combinations produce more drugs being administered are large and that even inefficient systems deliver enough drug to than 50% of the particle size output less than 5 m diameter and have an MMD of less than ensure maximal bronchodilatation. 5 m.
7 16 19-21 The lower flow rate combinations have less than 40% of their particle size output below 5 m diameter and an MMD of more than 9 m. The performance of some of the nebuliser chambers is given in table 2. Particle size distributions may differ with different combinations of nebuliser and compressor (fig 2) . Breath assisted nebulisers such as the Ventstream and Pari LC have been shown to have improved performance. 23 An important point about nebulising bronchodilator drugs is whether or not there is a need for a specific combination or combinations. 3) . 12 Where the residual volume is flow rate systems appear to be adequate, 30 31 greater than 1.0 ml, a larger initial fill volume especially since there appears to be little differis required. Since many nebuliser drugs are now ence in the rate of output of saline and of available in prepackaged ampoules of 2.0 ml bronchodilators. 14 or 2.5 ml, it is important to ensure that the nebuliser chamber used by a patient either has a small residual volume or that the patient is DN instructed to dilute the contents of the ampoule Current recommendations are based on limited with normal saline and to make up the initial data. [32] [33] [34] [35] rhDNase should be nebulised using fill volume to at least twice the size of the a jet nebuliser since ultrasonic nebulisers may residual volume. (2) The time taken to deliver the drug is important for patient compliance. The optimum time for nebulisation is 5-10 minutes.

Patients will generally not accept long delivery These can be nebulised with medium or high times (fig 4) , especially if the treatment is repower systems as shown in table 5. quired several times per day.
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(3) The end point of nebulisation needs to be defined. There is some evidence that Volume-time output and fill volume nebulising "to dryness" is confusing for patients Four criteria should be considered:
and is difficult for them to define (fig 5) . Jet (1) The minimum initial fill volume is denebulisers nebulise continuously until the fill termined by the size of the residual volume of volume approaches the residual volume and the nebuliser chamber. The larger the residual "spluttering" occurs. 36 At this point, although volume, the greater the initial fill volume will need to be. 9 17 22 The residual volume of the modern, small volume, nebuliser chambers is Table 5 Examples of nebuliser/compressor combinations less than 1.0 ml (table 2) and for these a fill suitable for corticosteroid therapy volume of 2.0-2.5 ml of drug solution is
Compressor
Nebuliser chamber It is taken that at least 50% of the drug solution should be available for nebulisation and without the need for dilution with normal saline. Data from British National Formulary. † Also available in 1.0 ml ampoules containing 250 g/ml. The 2.0 ml ampoule contains 500 g/ml. Use of the 1.0 ml ampoule will need dilution as no nebuliser chamber has a residual volume of less than 0.5 ml.
volume output is reduced because of evaporation, drug output remains high for a short period of time (fig 6) . This suggests that patients should be told to nebulise until spluttering occurs and then to continue for a further minute. Previous tests should have shown that, with the fill volume used, the system reaches this point in 10 minutes or less. It is essential that the compressor/nebuliser combination is working efficiently and has no faults. (4) During nebulisation (particularly with new units) large particles tend to adhere to the sides of the nebuliser. Adherence becomes less as the nebuliser ages. These large particles can be encouraged to fall back into the well of the chamber by tapping the side of the nebuliser chamber once the nebuliser begins to "splutter". There is evidence that this may improve output by up to 50% over a given period of time (fig 7) . The choice of nebuliser chamber should, to general, chambers should (1) not contain components that can be easily swallowed by small children (ideally, all nebulisers should consist of a removable top and the single component chamber); (2) be easily disassembled and reassembled by patients of all ages (this is particularly important in the elderly and in patients whose manual dexterity is significantly impaired); and (3) employ a chamber that can be left connected to the compressor, rest on a flat surface, or be mounted on the compressor itself, and so be filled easily. steroids or anticholinergics are being nebulised.
Ease of use

Mouthpieces/face masks and venting
group.bmj.com on June 23, 2017 -Published by http://thorax.bmj.com/ Downloaded from potential problems in patients with glaucoma. There have been no long term studies but short term studies in normal subjects and in patients with narrow angle glaucoma show that up to four times the recommended dose of inhaled ipratropium has no effect on intraocular pressure, pupil diameter, or accommodation.
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However, prolonged pupillary dilation occurs if ipratropium is sprayed directly into the eye. 42 The addition of salbutamol intensifies the risk, especially in patients with glaucoma, 43 44 so patients should be carefully instructed in the use of nebulised anticholinergic agents, ensuring that a face mask is tight fitting, or preferably, that administration occurs via a mouthpiece.

There are possible risks to staff associated with exposure to antibiotics (see paper by Webb and Dodd on pp S69-71), so it is important that the circuit should contain either a filter or the exhaled air be vented directly to the external atmosphere by wide bore tubing through an open window. Where appropriate filters are available, these should be used in preference to venting. Mouthpieces should be used.
Appropriate antibiotic T-pieces and circuitry is important to prevent waste from the system polluting the surrounding atmosphere, although there is no published medical evidence to indicate that pollution of the hospital atmosphere may lead to the establishment of resistant organisms.
, 
Mouthpieces are the preferred option.
Single use or single patient use?
The Medical Devices Agency has recently issued a bulletin 45 regarding the use of devices such as nebulisers for single use or single patient use. Where nebulisers are marked by the manufacturer as "single use" they may only be used once and should then be discarded. Where nebulisers are marked "single patient use" then they are reusable items that are capable of being reused, with or without reprocessing, by an indicated by the manufacturer, is followed. should define the extent and the methods by which "single patient use" devices should be used and reprocessed. Within the letter of the If a face mask is used it should be closely fitting to the face and should not be held away from law, devices marked "single use" should only be used once and then discarded. Reusing such the face.
devices may leave the physician and/or the respiratory team open to litigation should any problem arise as a result of using a "single  Usually the choice depends on patient pref-use" device as a "single patient use" device.
Manufacturers should mark the packaging of erence. Use of ipratropium bromide poses must ensure that he or she uses the correct type of device and, if in doubt, should contact the supplier directly. Items that contain no indication of use should be avoided. One major problem with nebuliser chambers is their potential for cross-infection. To date there does not appear to be any evidence that these devices are responsible for the acquisition of infecting organisms, although bacterial cultures of non-pathogenic organisms have been reported. 46 47 It is therefore important that good hygienic practice is followed 48 to reduce, as far as possible, any risk of infecting organisms being colonised within the nebuliser chamber.
Further research into this and into aspects of the degradation of nebuliser performance with time are required to clarify the need for carefully defining how nebuliser chambers are used in practice. All compressors should be certificated to British Standard 5724 or to an European equivalent. The certificate should be from an independent testing authority which should be stated by the manufacturer. is particularly important to patients who have to travel with their system. 7 16 The weights of various compressor/nebuliser combinations are  shown in fig 9. Noise can be an important factor in the acceptability of treatment, both to the patients and to their families and friends. The system should be as quiet as possible. An assessment  Running costs may be an important conof the noise of a range of devices is depicted in fig 8 which shows the range and how it sideration for patients with limited income.
Compressors: other factors for
Low energy consumption units would therefore relates to a variety of defining points used to assess noise pollution. 7 be appropriate for these patients, so long as the other performance requirements were met. Figure 10 shows the relative costs of various compressors where a patient has four 15 minute  To be portable, the compressor and associated nebulisations/day for one year. 7 These costs are calculated from the power rating components should be as light as possible. This constant rate, with the particle size such that most are less than 5 m. For other substances the evidence is less clear.
For the future
The major problem encountered in choosing the appropriate combination of nebuliser and compressor is the scarcity of consistent information. There is clearly a need for the assessment of all possible combinations currently available, and there must also be a clear consensus as to what information is essential and what is helpful but secondary in use.
To provide information on every combination of nebuliser and compressor will be difficult, time consuming, and expensive. However, if a number of laboratories were to be accredited to perform comparisons to set protocols, much of the difficulty in making statements about nebuliser and compressor combinations for the various nebulised drugs would be reduced. 
